Cancer Urology

Онкоурология

1726-97761996-1812

Publishing House ABV Press

190

10.17650/1726-9776-2009-5-1-34-39

DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS

ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ

INTRAVESICULAR IMMUNOTHERAPY WITH BCG VACCINE AND INTERFERON-αα2B FOR NON-INVASIVE CARCINOMA OF THE URINARY BLADDER: RESULTS OF PROSPECTIVE RANDOMIZED STUDY

ВНУТРИПУЗЫРНАЯ ИММУНОТЕРАПИЯ ВАКЦИНОЙ БЦЖ И ИНТЕРФЕРОНОМ-Α2B ПРИ НЕИНВАЗИВНОМ РАКЕ МОЧЕВОГО ПУЗЫРЯ: РЕЗУЛЬТАТЫ ПРОСПЕКТИВНОГО РАНДОМИЗИРОВАННОГО ИССЛЕДОВАНИЯ

Minich

A. A.

Минич

А. А.

Belarus

Sukonko

O. G.

Суконко

О. Г.

Belarus

Rolevich

A. A.

Ролевич

А. И.

Belarus

N.N. Aleksandrov Republican Research-and-Production Center of Oncology and Medical Radiology, MinskГУ РНПЦ онкологии и медицинской радиологии им. Н.Н. Александрова, Минск

30032009

34393107201431072014

https://oncourology.abvpress.ru/oncur/article/view/190

Внутрипузырная иммунотерапия вакциной БЦЖ и интерфероном-α2b при неинвазивном раке мочевого пузыря: результаты проспективного рандомизированного исследования

1. Kirkali Z., Chan T., Manoharan M. et al.Bladder cancer: epidemiology, staging andgrading, and diagnosis. Urology2005;66(Suppl 6A):4—34.

Kirkali Z., Chan T., Manoharan M. et al.Bladder cancer: epidemiology, staging andgrading, and diagnosis. Urology2005;66(Suppl 6A):4—34.

2. Матвеев Б.П., Фигурин К.М., Каря-кин О.Б. Рак мочевого пузыря. М.: Вер-дана, 2001.

Матвеев Б.П., Фигурин К.М., Каря-кин О.Б. Рак мочевого пузыря. М.: Вер-дана, 2001.

3. Herr H.W. Tumor progression and sur-vival of patients with high grade, noninva-sive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 2000;163:60—62.

Herr H.W. Tumor progression and sur-vival of patients with high grade, noninva-sive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 2000;163:60—62.

4. Wolf H., Melsen F., Pederson S.E.,Nielson K.T. Natural history of carcinomain situ of the urinary bladder. Scand J UrolNephrol 1994;157:147.

Wolf H., Melsen F., Pederson S.E.,Nielson K.T. Natural history of carcinomain situ of the urinary bladder. Scand J UrolNephrol 1994;157:147.

5. Malmstrom P.U., Busch C., Norlen B.J.Recurrence, progression, and survival inbladder cancer: a retrospective analysis of232 patients with greater than or equal to5-year follow-up. Scand J Urol Nephrol1987;21:185—95. 6. Oosterlinck W., Lobel B., Jakse G. et al.Guidelines on bladder cancer. Eur Urol2002;41:105—12.

Malmstrom P.U., Busch C., Norlen B.J.Recurrence, progression, and survival inbladder cancer: a retrospective analysis of232 patients with greater than or equal to5-year follow-up. Scand J Urol Nephrol1987;21:185—95. 6. Oosterlinck W., Lobel B., Jakse G. et al.Guidelines on bladder cancer. Eur Urol2002;41:105—12.

7. Smith О., Labasky К., Cockett A. et al.Bladder cancer clinical guidelines panelsummary report on the management ofnonmuscle invasive bladder cancer (stagesTa, T1 and Tis). J Urol 1999;162:1697—701.

Smith О., Labasky К., Cockett A. et al.Bladder cancer clinical guidelines panelsummary report on the management ofnonmuscle invasive bladder cancer (stagesTa, T1 and Tis). J Urol 1999;162:1697—701.

8. Sylvester R.J., van der Meijden A.P.,Lamm D.L. Intravesical bacillus Calmette-Gue’rin reduces the risk of progression inpatients with superficial bladder cancer: ameta-analysis of the published results ofrandomized clinical trials. J Urol2002;168:1964—70.

Sylvester R.J., van der Meijden A.P.,Lamm D.L. Intravesical bacillus Calmette-Gue’rin reduces the risk of progression inpatients with superficial bladder cancer: ameta-analysis of the published results ofrandomized clinical trials. J Urol2002;168:1964—70.

9. Bohle A., Jocham D., Bock P.R.Intravesical bacillus Calmette-Guerin ver-sus mitomycin C for superficial bladdercancer: a formal metaanalysis of compara-tive studies on recurrence and toxicity. JUrol 2003;169:90—5.

Bohle A., Jocham D., Bock P.R.Intravesical bacillus Calmette-Guerin ver-sus mitomycin C for superficial bladdercancer: a formal metaanalysis of compara-tive studies on recurrence and toxicity. JUrol 2003;169:90—5.

10. Saint F., Salomon L., Quintela L. et al.Classification, favorising factors, preven-tion and treatment of adverse side-effectsassociated with the Bacillus Calmette-Gu?rin in the treatment of superficial blad-der cancer. Ann Urol 2002;36:120—31.

Saint F., Salomon L., Quintela L. et al.Classification, favorising factors, preven-tion and treatment of adverse side-effectsassociated with the Bacillus Calmette-Gu?rin in the treatment of superficial blad-der cancer. Ann Urol 2002;36:120—31.

10.

11. Koya M., Simon M., Soloway M.Complications of intravesical therapy forurothelial cancer of the bladder. J Urol2006;175:2004—10.

Koya M., Simon M., Soloway M.Complications of intravesical therapy forurothelial cancer of the bladder. J Urol2006;175:2004—10.

11.

12. Belldegrun A., Franklin J., O’Donnell M. et al. Superficial bladdercancer: the role of interferon-alpha. J Urol1998;159:1793—98.

Belldegrun A., Franklin J., O’Donnell M. et al. Superficial bladdercancer: the role of interferon-alpha. J Urol1998;159:1793—98.

12.

13. Herr H.W., Schwalb D.M., Zhang Z.F.et al. Intravesical bacillus Calmette-Guerintherapy prevents tumor progression anddeath from superficial bladder cancer: ten-year follow-up of a prospective randomizedtrial. J Clin Oncol 1995;13:1404—16.

Herr H.W., Schwalb D.M., Zhang Z.F.et al. Intravesical bacillus Calmette-Guerintherapy prevents tumor progression anddeath from superficial bladder cancer: ten-year follow-up of a prospective randomizedtrial. J Clin Oncol 1995;13:1404—16.

13.

14. Nseyo U.O., Lamm D.L. Therapy ofsuperficial bladder cancer. Semin Oncol1996;23:598—604.

Nseyo U.O., Lamm D.L. Therapy ofsuperficial bladder cancer. Semin Oncol1996;23:598—604.

14.

15. Coplen D.E. Long-term follow-up ofpatients treated with 1 or 2, 6-week coursesof intravesical bacillus Calmette-Guerin:analysis of possible predictors of responsefree of tumor. J Urol 1990;144(3):652—7.

Coplen D.E. Long-term follow-up ofpatients treated with 1 or 2, 6-week coursesof intravesical bacillus Calmette-Guerin:analysis of possible predictors of responsefree of tumor. J Urol 1990;144(3):652—7.

15.

16. Griffiths T.R., Charlton M., Neal D.E.,Powell P.H. Treatment of carcinoma in situwith intravesical Bacillus Calmette-Guerinwithout maintenance. J Urol2002;167:2408—12.

Griffiths T.R., Charlton M., Neal D.E.,Powell P.H. Treatment of carcinoma in situwith intravesical Bacillus Calmette-Guerinwithout maintenance. J Urol2002;167:2408—12.

16.

17. Glashan R.W. A randomized controlledstudy of intravesical а-2b interferon in car-cinoma in situ of the bladder. J Urol1990;144:658—61.

Glashan R.W. A randomized controlledstudy of intravesical а-2b interferon in car-cinoma in situ of the bladder. J Urol1990;144:658—61.

17.

18. Torti P.M. Alpha-interferon in superfi-cial bladder cancer: a Northern CaliforniaOncology Group study. J Clin Oncol1988;6:476—83.

Torti P.M. Alpha-interferon in superfi-cial bladder cancer: a Northern CaliforniaOncology Group study. J Clin Oncol1988;6:476—83.

18.

19. Chodak G.W. Intravesical interferontreatment of superficial bladder cancer.Urology 1989;34:84—6.

Chodak G.W. Intravesical interferontreatment of superficial bladder cancer.Urology 1989;34:84—6.

19.

20. Downs T. Pharmacological biocompat-ibility between intravesical preparations ofBCG and interferon-alfa 2b. J Urol1997:158:2311—6.

Downs T. Pharmacological biocompat-ibility between intravesical preparations ofBCG and interferon-alfa 2b. J Urol1997:158:2311—6.

20.

21. O'Donnell M.A. Experimental andclinical evidence of enhancement of BCGefficacy by adding interferon-alpha. J Urol1997;157:383. Аbstr 1502.

O'Donnell M.A. Experimental andclinical evidence of enhancement of BCGefficacy by adding interferon-alpha. J Urol1997;157:383. Аbstr 1502.

21.

22. Esuvaranthan K., Kamaraj R., Mohan R.S. et al. A phase IIB trial of BCGcombined with interferon alpha for bladdercancer. J Urol 2000;163:152—675 [Abstr].

Esuvaranthan K., Kamaraj R., Mohan R.S. et al. A phase IIB trial of BCGcombined with interferon alpha for bladdercancer. J Urol 2000;163:152—675 [Abstr].

22.

23. O’Donnell M.A., Krohn J., DeWolf W.C. Salvage intravesical therapywith interferon-α2b plus low dose BacillusCalmette-Guerin is effective in patientswith superficial bladder cancer in whombacillus Calmette-Guerin alone previouslyfailed. J Urol 2001;166:1300—5.

O’Donnell M.A., Krohn J., DeWolf W.C. Salvage intravesical therapywith interferon-α2b plus low dose BacillusCalmette-Guerin is effective in patientswith superficial bladder cancer in whombacillus Calmette-Guerin alone previouslyfailed. J Urol 2001;166:1300—5.

23.

24. O’Donnell M.A., Lilli K., Leopold C.et al. Interim results from a national multi-center phase II trial of combination bacillusCalmette-Guerin plus interferon alfa-2bfor superficial bladder cancer. J Urol2004;172:888—93.

O’Donnell M.A., Lilli K., Leopold C.et al. Interim results from a national multi-center phase II trial of combination bacillusCalmette-Guerin plus interferon alfa-2bfor superficial bladder cancer. J Urol2004;172:888—93.

24.

25. Joudi F.N., Smith B.J., O’Donnell M.A. et al. Final results from anational multicenter phase II trial of com-bination bacillus Calmette-Gue’rin plusinterferon alpha-2B for reducing recur-rence of superficial bladder cancer. UrolOncol 2006;24:344—8.

Joudi F.N., Smith B.J., O’Donnell M.A. et al. Final results from anational multicenter phase II trial of com-bination bacillus Calmette-Gue’rin plusinterferon alpha-2B for reducing recur-rence of superficial bladder cancer. UrolOncol 2006;24:344—8.

25.

26. O’Donnell M.A., DeWolf W.C.Bacillus Calmette-Guerin immunotherapyfor superficial bladder cancer. Newprospects for an old warhorse. Surg OncolClin N Amer 1995;4:189—92.

O’Donnell M.A., DeWolf W.C.Bacillus Calmette-Guerin immunotherapyfor superficial bladder cancer. Newprospects for an old warhorse. Surg OncolClin N Amer 1995;4:189—92.

26.

27. Keeley F.X. A comparison of the localimmune response to intravesical alpha-interferon and bacillus Calmette-Guerin(BCG) in patients with superficial bladdercancer. J Urol 1994;151:473. Аbstr 983.

Keeley F.X. A comparison of the localimmune response to intravesical alpha-interferon and bacillus Calmette-Guerin(BCG) in patients with superficial bladdercancer. J Urol 1994;151:473. Аbstr 983.

27.

28. Borden E.C., Groveman D.S., Nasu T.et al. Antiproliferative activities of interfer-ons against human bladder carcinoma celllines in vitro. J Urol 1984;132:800—4.

Borden E.C., Groveman D.S., Nasu T.et al. Antiproliferative activities of interfer-ons against human bladder carcinoma celllines in vitro. J Urol 1984;132:800—4.

28.

29. Fuchsberger N., Kubes M., Kontsek P.et al. In vitro antiproliferative effect ofinterferon alpha in solid tumors: a potentialpredictive test. Neoplasma 1993;40:293—6.

Fuchsberger N., Kubes M., Kontsek P.et al. In vitro antiproliferative effect ofinterferon alpha in solid tumors: a potentialpredictive test. Neoplasma 1993;40:293—6.

29.

30. Hawkyard S., James K., Prescott S. et al. The effects of recombinant humaninterferon-gamma on a panel of humanbladder cancer cell lines. J Urol1991;145:1078—82.

Hawkyard S., James K., Prescott S. et al. The effects of recombinant humaninterferon-gamma on a panel of humanbladder cancer cell lines. J Urol1991;145:1078—82.

30.

31. Stricker P., Pryor K., Nicholson T. et al. Bacillus Calmette-Guerin plus intrav-esical in-terferon alpha-2b in patients withsuperficial bladder cancer. Urology1996;48:957—61.

Stricker P., Pryor K., Nicholson T. et al. Bacillus Calmette-Guerin plus intrav-esical in-terferon alpha-2b in patients withsuperficial bladder cancer. Urology1996;48:957—61.